Acute idiopathic maculopathy after COVID-19 vaccination

Taiji Hasegawa; Yoka Sannomiya; Momoka Toyoda; Ichiro Maruko; Tomohiro Iida

doi:10.1016/j.ajoc.2022.101479

Acute idiopathic maculopathy after COVID-19 vaccination

Am J Ophthalmol Case Rep. 2022 Jun:26:101479. doi: 10.1016/j.ajoc.2022.101479. Epub 2022 Mar 9.

Authors

Taiji Hasegawa¹, Yoka Sannomiya², Momoka Toyoda¹, Ichiro Maruko¹, Tomohiro Iida¹

Affiliations

¹ Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
² Department of Ophthalmology, The Second Shiseikai Hospital, Tokyo, Japan.

Abstract

Purpose: We report a case of acute idiopathic maculopathy (AIM) that developed after COVID-19 vaccination.

Observations: A 54-year-old woman complained of a sudden decrease of visual acuity in her right eye one day after receiving a second COVID-19 vaccination (Pfizer). Fundus photograph showed a circular yellow lesion at the fovea in right eye. Optical coherence tomography revealed the thickening of retinal pigment epithelium and the presence of subretinal fluid. Three months after the initial visit, the BCVA and the fundus images had favorable recovery in the right eye.

Conclusions and importance: We describe a case of AIM after receiving COVID-19 vaccination. These findings may be a helpful in understanding the pathogenesis of AIM.

Keywords: Acute idiopathic maculopathy; COVID-19; Vaccination.

Publication types

Case Reports